To find peer-reviewed articles on a particular illness, simply scroll down this page BY ILLNESS, until you find what you are looking for. If you do not find any information on what you are looking for, please select the tab for EMAIL and send me your request.

Dermatitis: Castelli D, Colin L, Camel E, Ries G; “Pretreatment of skin with a Ginkgo biloba extract/sodium carboxymethyl-beta-1,3-glucan formulation appears to inhibit the elicitation of allergic contact dermatitis in man;” Contact Dermatitia, 38:3,123-6. Mar 1998.  Quote: “…Ginkgo biloba / carboxymethyl-beta-1,3-glucan formulation can mitigate against allergic contact dermatitis.”

Diabetes: Kida K, Inoue T, Kaino Y, Goto Y, Ikeuchi M, Ito T, Matsuda H, Elliott RB. “An immunopotentiator of beta-1,6;1,3 D-glucan prevents diabetes and insulitis in BB rats.”  Dept of Pediatrics, Ehime U Sch of Med, Japan; Diabetes Res Clin Pract 17(2):75-9, PMID 1425150; Aug 1992. Quote: The intravenous administration of 1 mg kg- 1 week- of beta-1,6;1,3 D-glucan from the age of 4 weeks decreased the cumulative incidence of diabetes from 43.3% to 6.7% and also incidence of insulitis from 82.4% to 26.3% at the age of 20 weeks. …These data indicate that immunopotentiators [beta-1,6;1,3 D-glucan] could modulate the autoimmune mechanisms directed to pancreatic islets and inhibit the development of diabetes in BB rats.”

Diabetes / Glucose Controlr: Pola P, “Composition for the prevention and/or treatment of lipid metabolism disorders and allergic forms,” U.S. Patent Application 20030017999, January 23, 2003. “.beta-1,3-D-glucan has proved effective not only in preventing lipid metabolism disorders, but also in stimulating immune defenses, in preventing onset of tumors and in controlling serum glucose.

Diabetes: Carrow, D.J.; “Beta-1,3-glucan as a Primary Immune Activator,” Townsend  Letter; June 1996. Quote: “The following list includes benefits from the use of Beta 1,3-glucan supplementation: …people with chronic degenerative disorders such as diabetes or chronic inflammation. …

Diabetes: Kida K., Inoue T., et al; “An immunopotentiator of beta-1,6;1,3 D-glucan prevents diabetes and insulitis in BB rats.” Diabetes. Res. Clin. Pract. 17:75-79. 1992.  Quote:The preventive effect of an immunopotentiator, beta-1,6;1,3 D-glucan, on the development of diabetes and insulitis was studied in BB rats….[and] decreased the cumulative incidence of diabetes from 43.3% to 6.7% and also the incidence of insulitis from 82.4% to 26.3%….These data indicate that immunopotentiators could modulate the autoimmune mechanisms directed to pancreatic islets and inhibit the development of diabetes in BB rats.”

Diabetes: Lang C.H., Dobrescu C.; “Interleukin-1 induced increases in glucose utilization are insulin mediated.” Life Sciences; 45(22):2127-34. 1989.

Diabetes: Sherwood. E.R., et al., “Enhancement of Interleukin-1 and Interleukin-2 Production by Soluble Glucan,” International  Journal of Immunopharmacology.; 9:(3):261-267. 1987.

Dosage: Hunter KW, Gault RA, Berner MD, “Preparation of microparticulate B-glucan from Saccharomyces cerevisiae for use in immune potentiation.” Letters in Applied Microbiology,” Vol 35 Issue 4, 267-271, October 2002 (commercially MG Beta Glucan)Quote: …we compared the ability of orally administered microparticulate and aggregated B-glucan preparations given at 0·1 mg kg 1 daily for 14 d to enhance peritoneal macrophage phagocytosis. Note that this dosage is equivalent to a 10-mg capsule of B-glucan given orally to a 75-kg human. … It appears that the same dose of microparticulate B-glucan is better able to enhance macrophage phagocytosis than aggregated B-glucan.”

Dosage: U. of Nev School of Medicine and Nutritional Supply Corporation, “Beta Glucan Research Project Report,” Press Release, Feb 1, 2000

Quote: “The preliminary dose response studies demonstrate that oral doses of micronized MG glucan equivalent to 10 mg per day in humans provided significant immunopotentiation in mice.”

Dosage: U. of Nev School of Medicine and Nutritional Supply Corporation, “Beta Glucan Project Preliminary Findings,” Press Release, October 8, 1999

Quote: “Moreover, studies in mice included in the extensive research project at the University of Nevada School of Medicine have demonstrated a strong immunopotentiating effect in doses [of MG Beta Glucan] that would be equivalent to a human dose of 10 milligrams.”

Esherichia coli: Tzianabos AO, Cisneros RL; “Prophylaxis with the immunomodulator PGG glucan enhances antibiotic efficacy in rats infected with antibiotic-resistant bacteria,” Ann NY Acad Sci 797: 285-287; Oct 1996.* Quote: Results of these studies demonstrated that prophylaxis with PGG glucan in combination with antibiotics provided enhanced protection against lethal challenge with Escherichia coli or Staphylococcus aureus as compared with the use of antibiotics alone.”

Escherichia coli: Onderdonk, A.B., et al., “Anti-Infective Effect of Poly-.beta.1-6 -Glucotrisyl-.beta.1-3-Glucopyranose Glucan In Vivo,” Infec. Immun.; 60:1642-1647. 1992.  Dept of Pathology, Channing Lab, Brigham and Women’s Hospital, Boston, MA.* Quote: Mice challenged with Escherichia coli or Staphylococcus aureus were protected against lethal peritonitis by the intravenous administration of 10 micrograms of poly-beta 1-6-glucotriosyl-beta 1-3-glucopyranose (PGG) glucan per animal 4 to 6 h prior to bacterial challenge.”

Escherichia coli : Rasmussen, LT, Konopski Z, Oian P, Seljelid R; “Killing of Escherichia coli by mononuclear phagocytes and neutrophils stimulated in vitro with beta-1,3-D-polyglucose derivatives,” Microbiol Immunol 36(11):1173-1188. Inst of Med Bio, U of Tromso, Norway. 1992.*

Escherichia coli : Rasmussen LT, Seljelid R, “Dynamics of blood components and peritoneal fluid during treatment of murine E. coli sepsis with beta-1,3-D-polyglucose derivatives. I. Cells.,” Scand J Immunol 32(4): 321-331. Oct 1990.*

Escherichia coli:  Williams D.L., et al; “Effect of glucan on neutrophil dynamics and immune function in Escherichia coli peritonitis.” J. Surg. Res. 44:54-61, 1988.

Escherichia coli: Almdahl SM,  Seljelid R; “Semisoluble animated glucan: long-term efficacy against an intraperitoneal E. coli challenge and its effect on formation of abdominal adhesions,” Res Exp Med (Berlin) 187(5): 369-377, 1987.*

Escherichia coli: Almdahl SM, Bogwald J., Hoffman J., Sjunneskog C.; “The effect of splenectomy on Escherichia coli sepsis and its treatment  with semisoluble animated glucan,”, Scand J. Gastroenterol, 22:261-267, 1987.

Escherichia coli: Seljelid R., et al., ”The protective effect of beta 1-3D-glucan-derivatized plastic beads against Escherichia coli infection in mice,” Scand J. Immuno 25(1):55-60. Jan 1987.* Quote: “Pretreatment with beta-1,3-D-glucan-drivatized plastic beads conferred strong protection against Escherichia coli infection in mice.”

Escherichia coli : Rasmussen, LT, Fandrem. Jr., and Seljelid R., “Dynamics of Blood Components and Peritoneal Fluid During Treatment of Murine E. Coli Sepis with . beta.-1,3-D-polyglucose Derivatives”; Scand. J 63:73-80 Immunol. 1985.

Escherichia coli:  Williams D.L, Browder IW and DiLuzio N.R,”Immunotherapeutic modification of Escherichia coli—induced experimental peritonitis and bacteremia by glucan,” Surgery 93(3):448-454. Mar 1983.* Quote: “These data denote that the intraperitoneal administration of glucan significantly modifies the course of E. coli-induced peritonitis and bacteremia due, in part, to glucan-induced enhancement of macrophage function.

Fibromyalgia: – (Similar to Chronic Fatique) See Auto-Immune Disorders

Free Radical Scavinger: Sener G, Eksioglu-Demiraop E, Cetiner M, Ercan F, Yegen BC;  “beta-glucan ameliorates methotrexate-induced oxidative organ injury via its antioxidant and immunomodulatory effects.” European J Pharmacology; 542(1-3):170-178; Epub May 2006. Aug 7 2006. Quote: “Methotrexate is an antifolate [antimetabolite chemotherapy drug] that is widely used in the treatment of rheumatic disorders and malignant tumors. The efficacy of methotrexate is often limited by severe side effects and toxic sequelae [disease condition caused by a disease], where oxidative stress [free radical damage] is noticeable. … Thus, the findings of the present study suggest that beta-glucan, through its antioxidant and immunoregulatory effects, may be of therapeutic value in alleviating the leukocyte apoptosis [white immune cell death], oxidative [free radical] tissue injury and thereby the intestinal and hepatorenal [liver or kidney] side effects of methotrexate treatment.”

Free Radical Scavenger: Carrow, D.J.; “Beta-1,3-glucan as a Primary Immune Activator,” Townsend  Letter; June 1996. Quote: “Free radical scavenging assays were repeated in different models, which then confirmed the antioxidant effect of beta 1,3-glucan.  In light of what is presently known about the potential of free radicals to accelerate aging, cause cancer and other degenerative diseases, this particular effect of beta 1,3-glucan is especially important.”

Free Radical Scavenger: Anti-free Radical Activity of Beta(1-3)glucan Molecule. Seporga Laboratories, Sophia Antipolis, France. Research Report. 1990.

Free Radical Scavenging:  Patchen M.L., D’Alesandro M.M., Brook I., Blakely W.F. McVittie T.J.; “Glucan: Mechanisms Involved in Its ‘Radioprotective’ Effect”. J Leuc Biol.; 42:95-105. 1987. Quote: …evidence suggest that glucan can also function as an effective free radical scavenger.”

Free Radicals: Sener G, Toklu H, et al; “Protective effect of beta-glucan against oxidative organ injury in a rat model of sepsis,” Int Immunopharmacol:1387-96 Epub 2005/Aug 2005. Quote: “Sepsis leads to various organ damage and dysfunction. One of the underlying mechanisms is thought to be oxidative damage due to generation of free radicals. Elevated plasma TNF-alpha levels in septic rats [was] significantly reduced to control levels in beta-glucan treated rats. Since beta-glucan administration reversed these oxidant responses, it seems likely that beta-glucan protects against sepsis-induced oxidative organ injury.”

Fungal  Defense: Goodridge H, Reyes C, Becker C et al; “Activation of the innate immune receptor Dectin-1 upon formation of a ‘phagocytic synapse'” Nature, Vol 472 p 471-475, April 28, 2011. * Quote: “…Dectin-1 is a pattern-recognition receptor expressed by myeloid phagocytes (macrophages, dendritic cells and neutrophils) that detects b-glucans in fungal cell walls and triggers direct cellular antimicrobial activity… . Despite its ability to bind both soluble and particulate B-glucan polymers, Dectin-1 signaling is only activated by particulate B-glucans. …Studies in mice and humans have demonstrated an important role for Dectin-1 in anti-fungal defense. Dectin-1 signals activate anti-microbial phagocytosis, production of ROD [reactive oxygen species] and inflammatory innate immune responses, and influences the development of adaptive immunity…”

Fungal Diseases: The Biological activity of beta-glucans”; Minerva Medical; 100(3):237-245; Pub Med 19571787;  Jun 2009; Quote: “…Beta-glucans have studied for their hypocholesterolemic effects; these mechanisms include: reducing the intestinal absorption of cholesterol and bile acids by binding to glucans; shifting the liver from cholesterol syntheses to bile acid production; and fermentation by intestinal bacteria to short-chain fatty acids, which are absorbed and inhibit hepatic cholesterol syntheses. …beta-1,3-glucans improve the body’s immune system defense against foreign invaders by enhancing the ability of macrophages, neutrophils and natural killer cells to respond to and fight a wide range of challenges such as bacteria, viruses, fungi, and parasites. …there is renewed interest in the potential usefulness of beta-glucan as a radioprotective drug for chemotherapy, radiation therapy and nuclear emergencies, particularly because glucan can be used not only as a treatment, but also as a prophylactic [taken in advance for protection].”

Fungal Diseases: Silva E, Azevedo CD, et al; “The use of glucan as immunostimulant in the treatment of a severe case of chromoblastomycosis” [chronic fungal skin disease]; Dept. of Patologia [Pathology], U Federal do Maranhao Maranhao, Brazil; Mycoses, April 26, 2008; Quote: “We report the case of an alternative treatment for a patient with a severe form of chromoblastomycosis [chronic fungal skin disease] that responded poorly to the traditional antifungal therapy. We hereby show, in this study, the improvement of lesions after treatment with itraconazole associated with an intra muscular administration of glucan. We observed that the regression of lesions was associated with an improvement of the cellular immune response.”

Fungal Diseases:  Schorey JS, Lawrence C; “The pattern recognition receptor Dectin-1: from fungi to mycobacteria.” Curr Drug Targets. 9(2):123-9; Dept of Bilogical Sciences, U of Notre Dame. Feb 9, 2008. Quote: The ability of the innate immune system to quickly recognize and respond to an invading pathogen is essential for controlling the infection. For this purpose, cells of the immune system express receptors which recognize evolutionarily conserved structures expressed by various pathogens but absent from host cells. …Dectin -1 is a type II transmembrane protein which binds beta-1,3 and beta-1,6 glucans. It [Dectin-1`] is expressed on most cells of the innate immune system and has been implicated in phagocytosis as well as killing of fungi by macrophages, neutrophils and dendritic cells.”

Fungal Diseases and Pathogens: Hunter KW, Jr. Berner MD, Sura ME Alvea BN, “IFN-gamma primes macrophages for enhanced TNF-alpha expression in response to stimulatory and non-stimulatory amounts of microparticulate beta-glucan.,” Immunol Letters ; 15:98(1): 115-22. Department of Microbiology and Immunology, University of Nevada School of Medicine, Applied Research Facility, MS-199, Reno, NV 89557, USA. April 2005, Quote:  …”we have tested a new microparticulate form of beta-(1–> 3)-D-glucan (MG) from Saccharomyces cerevisiae for its ability to induce proinflammatory cytokine secretion in mouse peritoneal macrophages in vitro, and we have examined the effect of IFN-gamma. MG was rapidly phagocytized by peritoneal macrophages, and these MG-treated macrophages upregulated TNF-alpha, IL-6, and IL-1beta mRNAs and secreted these proinflammatory cytokines. These data suggest that a synergy between IFN-gamma and beta-glucan may have evolved to lower the threshold of sensitivity of the innate immune response to fungal pathogens.” [respond faster in attacking fungal pathogens – mycotoxins]

Fungicidal Activity: Pelizon AC, Kaneno R, et al; “Immunomodulatory activities associated with beta-glucan derived from Saccharomyces cerevisiae.”  Dept of Microbiology and Immunology, Inst of Biosciences, State U of Sao Paulo Brazil. Physio Res. 54(5):557-64 2005. Quote: “B-glucan enhances fungicidal activity against P. brasiliensis...B-glucan primes for higher IL12 and TNF-alpha production….B-glucan increases NK [Natural Killer white immune cells]. …The lower dose [20 mg/ml] was more effective to increase NK and fungicidal activity….Together, our results suggest that B-glucan derived from S. cerevisiae is able to improve Immune functions that contribute to P. brasiliensis elimination.”  Note: The mitosporic fungus, Paracoccidioides brasiliensis, is the causative agent of a true systemic (endemic) mycosis [fungus] called paracoccidioidomycosis (PCM) common in parts of South America.

Fungal Diseases and Immunity: Brown G D, Gordon Siamon; “Fungal B-Glucans and Mammalian Immunity.” Sir William Dunn Sch of Pathology, U of Oxford, UK, Immunity, Vol19, 311-316, 2003.  Quote:B-Glucans are structural cell wall polymers of many fungi which possesses  immunomodulatory activities. …The innate immune response is essential for the control of fungal infections, and there is increasing evidence that B-glucans are involved in initiating many aspects of this response.  The recognition of fungal pathogens occurs through both opsonic (mainly complement) and nonopsonic mechanisms, and as conserved structural components, B-glucans…play an important role in the non-opsonic recognition of these [fungal] pathogens. 

Indeed, many of the B-glucan receptors…have been shown to contribute to the recognition and phagocytosis of these organisms [fungal pathogens].  … B-glucans, especially in particulate form, can produce proinflammatory and antimicrobial responses through the TLRs and Dectin-1 [cell receptors for B-glucan]. Many of these responses are required for the control of fungal infections, such as the production of TNF-Alpha, and is an essential early cytokine required for the control of infections with C. albicans, A. fumigatus, C. neoformans, and H capsulatum. This is also true for IL-12, another important anti-fungal cytokine… . Thus B-glucans appear to have an important role in the innate immune response to fungal pathogens and in initiating a protective adaptive response.”

Fungal Pathogen Control: Brown G D, Gordon Siamon; “Fungal B-Glucans and Mammalian Immunity.” Sir William Dunn Sch of Pathology, U of Oxford, UK, Immunity, Vol19, 311-316, 2003.  Quote:“…the recognition of B-glucans in both [vertebrate and invertebrate] systems results in the triggering of immune responses, designed primarily for the control of fungal pathogens.

Fungal Diseases: Browder IW., Williams D., Pretus H., et al; Beneficial Effect of Enhanced Macrophage Function in the Trauma Patients. Ann. Surg.;  Vol 211: 605-613. Dept of Surg and Physiol, Tulane U Sch of Med, LA and Istituto Di Chirurgia D’Urgenza, U of Torino, Torino, Italy.* 1990. Quote: “Previous studies have demonstrated that glucan, a beta-1,3-linked glucopyranose polymer, isolated from the inner cell wall of Saccharomyces cerevisiae, is a potent  macrophage stimulant and is beneficial in the therapy of experimental bacterial, viral, and fungal diseases. “

Fungal Infection: Jamas S, Easson D, Ostroff G: “Underivatilized aqueous soluble beta (1,3) glucan, composition and method of making same.” U.S. Patent Application 20020032170, March 14, 2002. Quote: The use of soluble and insoluble beta glucans alone or as vaccine adjuvants for viral and bacterial antigens has been shown in animal models to markedly increase resistance to a variety of bacterial, fungal, protozoan and viral infections.”

Fungal Infection: DiLuzio N.R.,”Immunopharmacology of glucan: a broad spectrum enhancer of host defense mechanisms,” Trends in Pharmacol. SCI., 4:344-347. Dept of Physiology, Tulane U, New Orleans, LA.* 1983. Quote: (p347) “The broad spectrum of immunopharmacological activities of glucan includes not only the modification of certain bacterial, fungal, viral and parasitic infections, but also inhibition of tumor growth.”

Fungal: Williams D.L., Browder I. and DiLuzio N.R., “Soluble phosphorylated glucan: methods and compositions for wound healing,”  U.S. Patent 4975421, Issued Dec 4, 1990. Quote: “The soluble phosphorylated glucans are useful for promoting the wound healing process. The soluble phosphorylated glucans are also useful for prophylactic and therapeutic applications against neoplastic, bacteria, viral, fungal and parasitic diseases.” 

Heart – Artherogenic progression: Vetvicka V, Vetvickova J; ; “Effects of yeast-derived beta-glucans on blood cholesterol and macrophage functionality.”  U of Louisville, Dept of Pathology, Louisville, KY 40202; March 2009. Quote: consumption of …yeast-derived beta-glucan indicated a dose-dependent decrease in plasma cholesterol levels…highly purified yeast-derived beta-glucans modify cholesterol levels and other indicators associated with artherogenic progression in mice..”

Heart – Coronary Artery Bypass Grafting:  Asrsaether E, Rydningen M, et al; “Cardioprotective effect of pretreatment with beta-glucan in coronary artery bypass grafting.” Dept of Cardiothoracic and Vascular Surgery, Univ Hosp of N Norway, Norway. Sand Cardiovasc J. 40(5):298-304; PubMed 17012141. Oct 2006. Quote: The aims of the present study were to examine the safety of pretreatment with beta-1,3/1,6-glucan in patients scheduled for coronary artery bypass grafting (CABG), and to investigate whether beta-1,3/1,6-glucan pretreatment could suppress inflammatory response and protect against ischemia-reperfusion injury following CABG.  ……Twenty one patients scheduled for CABG were assigned to oral beta-1,3/1,6-glucan 700 mg (Group 1) or 1 400 mg (Group 2) five consecutive days before surgery and were compared with a control group (Group 3). Blood samples were drawn preoperatively and on the first, third and fifth postoperative day for analysis of acute-phase reactants, hematology, cytokines and myocardial enzymes. CONCLUSIONS: Beta-1,3/1,6-glucan pretreatment is safe in patients undergoing CABG [Coronary artery bypass grafting] and may protect against ischemia reperfusion injury following CABG.

Heart – Coronary Artery Disease: Robert Nicolosi, Stacey J Bell, Bruce R Bistrian, Isaac Greenberg, R Armour Forse and George L Blackburn, “Cholesterol Benefits from Beta 1,3/1,6 Glucan Purified from Yeast Cell Wall,” Nutrition and Infection Laboratory, Harvard Medical School; the Centers for the Study of Nutrition and Medicine and for Nutritional Research, and Clowes Surgical Metabolism Laboratory, Beth Israel Deaconess Medical Center, Boston. American Journal of Clinical Nutrition, Vol. 70, No. 2, 208-212, August 1999. Quote:The purpose of this study was to evaluate the effecton serum lipids of a yeast-derived ß-glucan fiber in 15free-living, obese, hypercholesterolemic men. …The yeast-derived ß-glucan fiber significantlylowered total cholesterol concentrations and was well tolerated…The link between elevated plasma LDL-cholesterol concentrationsand the risk of developing coronary artery disease has beenclearly established…Elevated plasma cholesterol and, in particular, LDL-cholesterolconcentrations are associated with increased risk of coronaryartery disease, whereas an elevated of HDL-cholesterol concentrationis inversely correlated with the incidence of cardiovascular…The yeast-derived ß-glucan fiber lowered total cholesteroland raised HDL-cholesterol concentrations significantly. …

Unlike the significant increases in HDL-cholesterol concentrationsobserved 4 wk after the end of the study for subjects receivingthe yeast-derived ß-glucan, none of the 24 studies ofoat products reported significant changes in HDL concentration.Because higher HDL-cholesterol concentrations are associated with a reduced risk of developing coronary artery disease, there may be unique benefits of usingthe yeast-derived ß-glucan, and perhaps psyllium, ratherthan the oat products.

Heart Disease: Carrow, D.J.; “Beta-1,3-glucan as a Primary Immune Activator,” Townsend  Letter; June 1996. Quote: “…immunosuppression is observed in people with stress-related disease such as coronary heart disease.  Under such influences the number of macrophages [white immune cells] available are reduced and unable to participate in the immune cascade, which caused an even greater immunosuppression.

 Beta 1,3 glucan has proven to both stimulate and activate the macrophage cells, which will counter these negative effects. …People with high risk of atherosclerosis should definitely add beta 1,3 glucan to their diet in addition to any cholesterol-reducing drugs.

 Macrophage activation helps draw extra cholesterol from the blood, prevent further plaque formation on the arterial walls and phagocytes [eats] existing plaque which is recognized as a foreign body.”

Heart Disease: Bell S, Goldman VM, Bistrian BR, Arnold AH, Ostroff G, Forse RA, “Effect of beta-glucan from oats and yeast on serum lipids [cholesterol included],”  Critical  Rev Food Science Nutrition, Harvard Medical School, Boston, MA; 39(2):189-202, March 1999: Quote: Heart disease is the leading cause of death in the U.S.  One way to reduce the risk of developing the disease is to lower serum cholesterol levels by making dietary changes. In addition to reducing intake of total fat, saturated fat and dietary cholesterol, serum cholesterol can be further reduced by added fiber, especially from sources rich in beta-glucan. …The yeast-derived fiber is a more concentrated source of beta-glucan than the oat product.”   

Hemopoietic (or hematopoietic) Recovery – Formation of Blood Cells: Daniel E Cramer, Daniel J Allendorf, Jarek T Baran, Richard Hansen, Jose Marroquin, Bing Li, Janina Ratajczak, Mariusz Z Ratajczak, and Jun Yan; Beta-glucan enhances complement-mediated hematopoietic recovery after bone marrow injury;” Blood; DOI 10.1182. Tumor Immunobiology Program and Stem Cell Biology Program, James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA. Sept 2005. Quote: “…Myelotoxic injury in the bone marrow (BM) as a consequence oftotal body irradiation (TBI) or granulocyte colony stimulatingfactor (G-CSF) mobilization results in the deposition of iC3bon BM [bone marrow] stroma [cell framework]. … Taken together, these observations suggest a novelrole for C, CR3, and Beta glucan in the restoration of hematopoiesisfollowing injury.” NOTE: Mice were treated for 12 days with beta glucan and exposed to a sublethal dose of radiation. The beta glucan treated animals had approximately 40 percent more cell formation units in the spleen than untreated mice. When beta glucan was given orally, survival of animals receiving a lethal dose of radiation after stem cell transplantation was significantly enhanced. Forty days following radiation exposure, approximately 30 percent of mice treated with beta glucan survived compared with only 3 percent of untreated animals.

Hemopoietic Recovery: Popisil, et al., “Glucan Induced Hemopoietic Recovery in Gamma-Irradiated Mice”.  Experientia; 38: 1232-1234. 1982.

Hemopoietic Stimulation: Patchen M.L., McVittie T.J.; Temporal Response of Murine Pluripotent Stem Cells and Myeloid and Erythroid Progenitor Cells to Low-dose Glucan Treatment. Acta Hemat; 70:281-288.  Experimental Hematology Dept, Armed Forces Radiobiology Research Insti, Bethesda, MD. 1983.  Quote: “Clearly, there are numerous possible uses for an agent such as glucan, which is a potent stimulator of hemopoietic activity. Currently, we [U.S. Armed Services] are using glucan to enhance hemopoietic proliferation in conjunction with hemopoietic injury induced by radiation.”

Hepatic Metastases : Sherwood. E.R., et al., ”Soluble Glucan and Lymphokine-activated Killer (LAK) Cells in the Therapy of Experimental Hepatic Metastases,” Chemical Abstracts; 108:179752V. 1988.

Hepatitis – Viral : Williams D.L. and DiLuzio N.R.; “Glucan-Induced Modification of murine Viral Hepatitis”.  Science (1980), 208: 67-69. 1980.* Quote: “Thus glucan is capable of increasing survival, inhibiting hepatic necrosis, and maintaining an activated state of phagocytic activity in mice challenged with [mouse hepatitis virus strain] MHV-A59.”

Hepatitis – Viral: Williams D.L. and DiLuzio N.R.,;“Modification of Experimental Viral Hepatitis by Glucan Induced Macrophage Activation”. in the Reticuloendothelial System and Pathogenesis of Liver Disease, Liehr and Grun, eds.  Elsevier/North Holland Biomedical Press; pp. 363-368. 1983.

Hepatitis:  “Modification of Experimental Viral Hepatitis By Glucan Induced Macrophage Activation”. Elesevier/North Holland Biomedical Press; pp. 363-368. 1980.

Herpes-simplex: Kohl, et al., “Inhibition of Human Monocyte-Macrophage and Lymphocyte Cytotoxicity to Herpes-simplex Cells by Glucan”.  J. Immunol. Methods; 29: 361-368. 1979.*  Quote: “Particulate, cell-associated glucan irreversibly inhibited MP antibody-dependent cellular cytotoxicity (ADCC).”

Herpes-simplex 1: Marchetti M, Pisani S, Pietropaolo V, Seganti L, Nicoletti R, Degener A, Orsi N; “Antiviral effect of a polysaccharide from Schlerotium glucanicum towards herpes simples virus type 1 infection.” Planta Med, 62:4, 301-7. Aug 1996. Quote: “The antiviral effect of scleroglucan seems to be related to its binding with membrane glycoproteins of HSV-1 particles which impedes the complex interactions of the virus with the cell plasma membrane.”

Hyperbaric oxygen and Glucan: Guzel S, Sunamak O, AS A, Celik V, Ferahman M, Nuri MM, Gazioglu E, Atukeren P, Mutlu O; “Effects of hyperbaric oxygen and Pgg-glucan on ischemic colon anastomosis.”  World J Gastroenterol: 7:12(9):1421-5. Mar 2006.  Quote: “… Here we analyzed the effects of hyperbaric oxygen and beta-glucan on colon anastomoses in ischemic condition. … CONCLUSION: Hyperbaric oxygen and glucan improve healing in ischemic colon anastomoses [surgical connection of two parts of the colon together] by anti-microbic, immune stimulating properties and seem to act synergistically when combined together.

Hyperlipemia: Donzis B. A.: Method and Composition for Treating Hyperlipemia. U.S. Patent 4,891,220; 1990.

Visit Today : 10
This Month : 204
Total Visit : 14307
plugins by Bali Web Design



Recent Posts